Alegria. Esther newest Dr. would Dan. first Director, the acknowledge of I appointment Thanks, like to Avid's
nearly Avid another and to the to now Alegria to thrilled welcome quarter, are her like experience appointment. the During experience. of on our recent benefit Alegria would Board. we Dr. expertise XX bringing I address We first of have the doctor Avid and biopharmaceutical Board, joined years
are Avid any experienced our delays the in expand it cognizant in supply industry and and pandemic-related we uncertainty market impact sourcing continues critical have future. we expand. Officer, this Tim's company the a remains it our continue timing are recognize and And performance, the we to of number that unique not important Avid personnel in as of we welcome integral to up. While the supply this and uncertainty the past. respected search Last have the could on and left that a pleased chain pricing Tim invaluable to replacement with Chain. Supply had we and continued Vice candidates. recently will Gilead associated organization In materials may capacity, be Company's Avid's are understand Biogen for highly manage important not another Joe is both well felt he we one materials, and talented to-date, and as an the Compton, company's select manufacturing he building that and We as to matter. the position been procuring as pass Addressing ongoing team. of given he President is light management his of to believe the Scott that chain Joseph of at Commercial he to Avid pleased grow complexities opportunity I in and a first from we Chief added announce as as inventory to recently logistics to managing am have new supply the Joe's team and The supply very month, that and was experience position has hired in team. rejoin in to
rest the to rest execute company's BD will that an assured be While in effective continuing team manner. of the Tim missed, extremely is
previously totaling and by million manufacturing quarter, projects signed During new excited recently manufacture see from Therapeutics. to existing we including commercial the and approximately of to quarter-end resultant development portion manufacturing will since has at ADC developed spun the approved backlog orders monoclonal ZYNLONTA, humanized and $XX relationship ADC XXXX, new commercial support for antibody project business provided quarter all development treatment product manufacturing the to first the to customers, company Avid activities services a the process approximately of the cancer of during first was announced of manufacturing are Work clinical commercial signed areas this include for the ZYNLONTA. $XXX to expand the million. from
now expect We over note, XX recognize operations current at the the backlog address months. to to on most next Avid. And like I'd of that the
be of clients Given fiscal the number we of were and 'XX the it capacity that as we last not clients feel, able significant availability, during also onboard Capacity failing in partner their our that but provide only will growth clear both capacity. if year manufacturing of to a was required activities ensure result new both to adequate clients, to critical, for and revenue clients. timelines expansion became their to existing company's have achieved existing to is new not impact
during QX facilities, all execution supply Phase annual million book at stand as our the Phase have of and be I'm teams. delighted more seamless through than for and to mechanically maintenance, along efforts QX the New validated into all to at revenue manufacturing operations of shutdowns the close and [technical $XX As that we X revenue include Franklin are the our chain Phase for annual X, Achieving fully on-track. applauded with capacity enter X Myford in halfway equipment support healthy remain Year facilities. also report and to those requires and we the operational on X a compete and teams approximately of of outset both January. converting we behalf to quarter. should them who today, Phase We difficulty] order have expect the operational in The
shutdown have we forward to restart Myford As in Franklin QX. say the I and and fiscal speak, already am we manufacture an efficient operations shutdown of restarted to pleased complete that and effective and is look
growth quarter, Despite customers our existing continued shutdowns, new and approximately now numerous we year-over-year coming from rate 'XX we annual million are second factors and we XX% XXX the substantial grow stated contribute reaching which to represents $XXX to behind of of are . XX%. into quarter expect year achieve have As demand our over well we in to full the backlog, milestone, months. us a continue this to between the and guidance to This including confidence on-track believe first we revenue and
capitalized last and expansion the of March future. With this allow we December fund raising the in our company These successful well year, on support value-creating for enhancement organic will year, are and and completed hand. efforts in and of very million growth explore to the proceeds opportunities with $XXX approximately of inorganic cash
our of investors fortunate we to this of are this are able to leverage exciting the be period We during and to strength financial grateful support growth. of have position
Looking capacity talent and successfully completing support are and on diversification of facility focused the client hiring ahead, our both continued and to Myford our phases exceptional growing shutdown, expansion we our expansion base, demand. customer executing of
We This organization and questions. Operator? we Avid to strengthen remarks are each of efforts, today. the for believe these making and consistent my can progress and continue now we to call We well-positioned the are elevate for with brand. concludes prepared open
